Product logins

Find logins to all Clarivate products below.


Thyroid Cancer – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of thyroid cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of  thyroid cancer for each country, as well as annualized case counts projected to the national population.

In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.

Clarivate Epidemiology’s thyroid cancer forecast will answer the following questions:

  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with thyroid cancer each year?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of thyroid cancer  over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

Note: Coverage may vary by country

Related Market Assessment Reports

Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Endometrial Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for endometrial carcinoma is rapidly evolving, driven by the growing adoption of immune checkpoint inhibitors and advancements in molecular classification. Although…
Report
Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (…
Report
Breast Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…
Report
Hepatocellular Carcinoma – Geographic Focus: China – Hepatocellular Carcinoma – China In-Depth (China)
The hepatocellular carcinoma therapy market in China is poised to experience significant growth, driven by an aging population and the high prevalence of hepatitis B and C infection. Angiogenesis…